| Previous Close | 2.00 |
| Open | 2.00 |
| Bid | 1.50 x 20000 |
| Ask | 2.15 x 200 |
| Day's Range | 2.00 - 2.05 |
| 52 Week Range | 1.50 - 8.35 |
| Volume | 248,912 |
| Avg. Volume | 1,131,120 |
| Market Cap | 156.84M |
| Beta | 1.89 |
| PE Ratio (TTM) | -1.61 |
| EPS (TTM) | -1.27 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- Accesswire•4 days ago
Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation
NEW YORK, NY / ACCESSWIRE / July 17, 2017 / Sorrento Therapeutics had a big insider purchase revealed last week that helped drive share prices higher. Omeros Corporation also saw big gains after announcing ...
- Capital Cube•20 days ago
ETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sorrento Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SRNE-US. Comparing the performance and risk of Sorrento Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•21 days ago
Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain
SAN DIEGO, June 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug Application (IND) for Resiniferatoxin (RTX), a non-opioid, TRPV1 agonist that selectively targets afferent nerve activation involved in chronic pain states. Sorrento intends to promptly initiate a multicenter, Phase 1b clinical trial of RTX administered by epidural injection for the treatment of intractable pain associated with cancer.
